Drug Trial Radar · NCT03024255
A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Last checked: Nov 20, 2026Latest source record: May 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
227
Actual
Start
Dec 22, 2016
Primary completion
Sep 19, 2017
Study completion Sep 19, 2017
Sponsor
- Lead sponsor
- Botanix PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to assess the safety and efficacy of 3 concentrations of BBI-4000 and vehicle (4 treatment arms), applied for the treatment of axillary hyperhidrosis.
Conditions
- Hyperhidrosis
Interventions
BBI-4000 gel, 5%Drug
BBI-4000 gel, 5% applied once to each axilla daily
BBI-4000 gel, 10%Drug
BBI-4000 gel, 10% applied once to each axilla daily
BBI-4000 gel, 15%Drug
BBI-4000 gel, 15% applied once to each axilla daily
Vehicle (Placebo)Drug
Placebo, applied once to each axilla daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) Score From Baseline to End of TherapyTime frame: overall ~6 Weeks, as listed in description includes: Baseline-Visit 1, Visit 4 and End of Therapy Visit - Days 41, 42, 43.
- Number (%) of Subjects Reporting at Least One Treatment Emergent Adverse Event by SeverityTime frame: Treatment initiation through end of treatment (~42 days) and subsequent safety f/u (~14 days following end of treatment)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.